

# Anita Riecher-Rössler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/651591/publications.pdf>

Version: 2024-02-01

319  
papers

19,883  
citations

14655

66  
h-index

13379

130  
g-index

377  
all docs

377  
docs citations

377  
times ranked

13015  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Psychosis High-Risk State. <i>JAMA Psychiatry</i> , 2013, 70, 107.	11.0	1,222
2	Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. <i>Lancet</i> , The, 2008, 371, 1085-1097.	13.7	964
3	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. <i>Biological Psychiatry</i> , 2018, 84, 644-654.	1.3	627
4	The Influence of Age and Sex on the Onset and Early Course of Schizophrenia. <i>British Journal of Psychiatry</i> , 1993, 162, 80-86.	2.8	594
5	IRAOS: an instrument for the assessment of onset and early course of schizophrenia. <i>Schizophrenia Research</i> , 1992, 6, 209-223.	2.0	521
6	Size of burden of schizophrenia and psychotic disorders. <i>European Neuropsychopharmacology</i> , 2005, 15, 399-409.	0.7	516
7	EPA guidance on the early intervention in clinical high risk states of psychoses. <i>European Psychiatry</i> , 2015, 30, 388-404.	0.2	390
8	Accelerated Brain Aging in Schizophrenia and Beyond: A Neuroanatomical Marker of Psychiatric Disorders. <i>Schizophrenia Bulletin</i> , 2014, 40, 1140-1153.	4.3	369
9	Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk. <i>JAMA Psychiatry</i> , 2016, 73, 113.	11.0	354
10	Sex and gender differences in mental disorders. <i>Lancet Psychiatry</i> , the, 2017, 4, 8-9.	7.4	334
11	EPA guidance on the early detection of clinical high risk states of psychoses. <i>European Psychiatry</i> , 2015, 30, 405-416.	0.2	318
12	Regional Gray Matter Volume Abnormalities in the At Risk Mental State. <i>Biological Psychiatry</i> , 2007, 61, 1148-1156.	1.3	295
13	Causes and Consequences of the Gender Difference in Age at Onset of Schizophrenia. <i>Schizophrenia Bulletin</i> , 1998, 24, 99-113.	4.3	289
14	Neuroimaging predictors of transition to psychosisâ€”A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2010, 34, 1207-1222.	6.1	287
15	Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST). <i>American Journal of Psychiatry</i> , 2009, 166, 675-682.	7.2	284
16	Psychotic experiences in the general population: A twenty-year prospective community study. <i>Schizophrenia Research</i> , 2007, 92, 1-14.	2.0	265
17	Can Estradiol Modulate Schizophrenic Symptomatology?. <i>Schizophrenia Bulletin</i> , 1994, 20, 203-214.	4.3	263
18	Intervention in Individuals at Ultra-High Risk for Psychosis. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1206-1212.	2.2	258

#	ARTICLE	IF	CITATIONS
19	Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression. <i>JAMA Psychiatry</i> , 2018, 75, 1156.	11.0	251
20	Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. <i>Psychological Medicine</i> , 1993, 23, 925-940.	4.5	249
21	Efficacy of Using Cognitive Status in Predicting Psychosis: A 7-Year Follow-Up. <i>Biological Psychiatry</i> , 2009, 66, 1023-1030.	1.3	244
22	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. <i>Schizophrenia Bulletin</i> , 2014, 40, 729-736.	4.3	229
23	Neuroanatomical Abnormalities That Predate the Onset of Psychosis. <i>Archives of General Psychiatry</i> , 2011, 68, 489.	12.3	227
24	How does gender influence age at first hospitalization for schizophrenia? A transnational case register study. <i>Psychological Medicine</i> , 1989, 19, 903-918.	4.5	226
25	Effect of $\omega$ -3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. <i>JAMA Psychiatry</i> , 2017, 74, 19.	11.0	216
26	Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. <i>Schizophrenia Research</i> , 2008, 106, 108-114.	2.0	210
27	At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. <i>World Psychiatry</i> , 2015, 14, 322-332.	10.4	209
28	The ABC schizophrenia study: a preliminary overview of the results. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 1998, 33, 380-386.	3.1	196
29	A Randomized, Double-Blind, Placebo-Controlled Study of Light Therapy for Antepartum Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 986-993.	2.2	195
30	The Effects of Antipsychotics on the Brain: What Have We Learnt from Structural Imaging of Schizophrenia? – A Systematic Review. <i>Current Pharmaceutical Design</i> , 2009, 15, 2535-2549.	1.9	191
31	The Basel early-detection-of-psychosis (FEPSY)-study – design and preliminary results. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 114-125.	4.5	187
32	The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. <i>Schizophrenia Bulletin</i> , 2016, 42, 732-743.	4.3	183
33	First onset and early symptomatology of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1992, 242, 109-118.	3.2	180
34	The Epidemiology of Early Schizophrenia. <i>British Journal of Psychiatry</i> , 1994, 164, 29-38.	2.8	178
35	Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. <i>Acta Psychiatrica Scandinavica</i> , 2000, 102, 58-62.	4.5	175
36	Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life-cycle. <i>Psychological Medicine</i> , 1998, 28, 351-365.	4.5	144

#	ARTICLE	IF	CITATIONS
37	Schizophrenia and oestrogens – is there an association?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1993, 242, 323-328.	3.2	143
38	Sex and gender differences in schizophrenic psychoses – a critical review. <i>Archives of Women's Mental Health</i> , 2018, 21, 627-648.	2.6	140
39	Disease Prediction in the At-Risk Mental State for Psychosis Using Neuroanatomical Biomarkers: Results From the FePsy Study. <i>Schizophrenia Bulletin</i> , 2012, 38, 1234-1246.	4.3	139
40	Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. <i>European Neuropsychopharmacology</i> , 2013, 23, 196-204.	0.7	137
41	Detecting the Psychosis Prodrome Across High-Risk Populations Using Neuroanatomical Biomarkers. <i>Schizophrenia Bulletin</i> , 2015, 41, 471-482.	4.3	136
42	Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. <i>Brain</i> , 2015, 138, 2059-2073.	7.6	132
43	Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. <i>British Journal of Psychiatry</i> , 2007, 191, s69-s75.	2.8	128
44	Compulsory admission of psychiatric patients – an international comparison. <i>Acta Psychiatrica Scandinavica</i> , 1993, 87, 231-236.	4.5	126
45	Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression. <i>JAMA Psychiatry</i> , 2021, 78, 195.	11.0	125
46	Moving beyond transition outcomes: Meta-analysis of remission rates in individuals at high clinical risk for psychosis. <i>Psychiatry Research</i> , 2013, 209, 266-272.	3.3	114
47	Acute Effects of Heroin on Negative Emotional Processing: Relation of Amygdala Activity and Stress-Related Responses. <i>Biological Psychiatry</i> , 2014, 76, 289-296.	1.3	112
48	Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. <i>Lancet Psychiatry</i> , 2017, 4, 63-72.	7.4	104
49	Sexual Dysfunction in First-Episode Schizophrenia Patients. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 274-280.	1.4	99
50	Further evidence for a specific role of estradiol in schizophrenia?. <i>Biological Psychiatry</i> , 1994, 36, 492-494.	1.3	97
51	Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. <i>Biological Psychiatry</i> , 1994, 36, 137-139.	1.3	96
52	Brain Connectivity Abnormalities Predating the Onset of Psychosis. <i>JAMA Psychiatry</i> , 2013, 70, 903.	11.0	94
53	The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial. <i>Schizophrenia Research</i> , 2005, 78, 147-156.	2.0	89
54	Factors influencing compulsory admission of psychiatric patients. <i>Psychological Medicine</i> , 1991, 21, 197-208.	4.5	88

#	ARTICLE	IF	CITATIONS
55	Neuropsychological deficits in individuals with an at risk mental state for psychosis – Working memory as a potential trait marker. <i>Schizophrenia Research</i> , 2007, 97, 14-24.	2.0	88
56	Validation of Danish case register diagnosis for schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 1994, 90, 196-203.	4.5	87
57	Whither the Attenuated Psychosis Syndrome?. <i>Schizophrenia Bulletin</i> , 2012, 38, 1130-1134.	4.3	85
58	Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. <i>Psychological Medicine</i> , 2013, 43, 2571-2582.	4.5	85
59	Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. <i>Journal of Psychiatric Research</i> , 2010, 44, 447-453.	3.1	82
60	Does case management reduce the rehospitalization rate?. <i>Acta Psychiatrica Scandinavica</i> , 1992, 86, 445-449.	4.5	78
61	Prediction of transition to psychosis in patients with a clinical high risk for psychosis: a systematic review of methodology and reporting. <i>Psychological Medicine</i> , 2017, 47, 1163-1178.	4.5	75
62	Early detection and treatment of schizophrenia: how early?. <i>Acta Psychiatrica Scandinavica</i> , 2006, 113, 73-80.	4.5	73
63	Hyperprolactinaemia in early psychosis – not only due to antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1342-1344.	4.8	72
64	Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 987-995.	2.1	69
65	Clinical and functional long-term outcome of patients at clinical high risk (CHR) for psychosis without transition to psychosis: A systematic review. <i>Schizophrenia Research</i> , 2019, 210, 39-47.	2.0	67
66	Domestic violence against women: Definitions, epidemiology, risk factors and consequences. <i>Swiss Medical Weekly</i> , 2010, 140, w13099.	1.6	67
67	Postpartum depression: do we still need this diagnostic term?. <i>Acta Psychiatrica Scandinavica</i> , 2003, 108, 51-56.	4.5	64
68	Can Cortical Thickness Asymmetry Analysis Contribute to Detection of At-Risk Mental State and First-Episode Psychosis?: A Pilot Study. <i>Radiology</i> , 2009, 250, 212-221.	7.3	64
69	Distinguishing Prodromal From First-Episode Psychosis Using Neuroanatomical Single-Subject Pattern Recognition. <i>Schizophrenia Bulletin</i> , 2013, 39, 1105-1114.	4.3	64
70	Estrogens and Gonadal Function in Schizophrenia and Related Psychoses. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 8, 155-171.	1.7	63
71	Different duration of at-risk mental state associated with neurofunctional abnormalities. A multimodal imaging study. <i>Human Brain Mapping</i> , 2012, 33, 2281-2294.	3.6	63
72	Aberrant Current Source-Density and Lagged Phase Synchronization of Neural Oscillations as Markers for Emerging Psychosis. <i>Schizophrenia Bulletin</i> , 2015, 41, 919-929.	4.3	60

#	ARTICLE	IF	CITATIONS
73	What do we really know about late-onset schizophrenia?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1997, 247, 195-208.	3.2	59
74	Help-seeking and pathways to care in the early stages of psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2013, 48, 1033-1043.	3.1	59
75	Oestrogen effects in schizophrenia and their potential therapeutic implications - Review. <i>Archives of Women's Mental Health</i> , 2002, 5, 111-118.	2.6	57
76	Pituitary volume increase during emerging psychosis. <i>Schizophrenia Research</i> , 2011, 125, 41-48.	2.0	57
77	Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence. <i>JAMA Psychiatry</i> , 2021, 78, 77.	11.0	57
78	Disorganized Gyrfication Network Properties During the Transition to Psychosis. <i>JAMA Psychiatry</i> , 2018, 75, 613.	11.0	56
79	Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, S1-207.	2.1	55
80	Do Subjects at Clinical High Risk for Psychosis Differ from those with a Genetic High Risk? - A Systematic Review of Structural and Functional Brain Abnormalities. <i>Current Medicinal Chemistry</i> , 2013, 20, 467-481.	2.4	55
81	NEURAPRO study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. <i>Microbial Biotechnology</i> , 2017, 11, 418-428.	1.7	55
82	Neuropsychological and neurophysiological findings in individuals suspected to be at risk for schizophrenia: preliminary results from the Basel early detection of psychosis study - Früherkennung von Psychosen (FEPSY). <i>Acta Psychiatrica Scandinavica</i> , 2003, 108, 152-155.	4.5	54
83	Clinical trajectories in the ultra-high risk for psychosis population. <i>Schizophrenia Research</i> , 2018, 197, 550-556.	2.0	54
84	The course of schizophrenic psychoses: what do we really know? A selective review from an epidemiological perspective. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998, 248, 189-202.	3.2	53
85	Prospects for the classification of mental disorders in women. <i>European Psychiatry</i> , 2010, 25, 189-196.	0.2	53
86	Effects of Cannabis Use on Human Brain Structure in Psychosis: A Systematic Review Combining In Vivo Structural Neuroimaging and Post Mortem Studies. <i>Current Pharmaceutical Design</i> , 2012, 18, 5070-5080.	1.9	53
87	Hippocampal volume in subjects at high risk of psychosis: A longitudinal MRI study. <i>Schizophrenia Research</i> , 2012, 142, 217-222.	2.0	52
88	EEG microstates as biomarker for psychosis in ultra-high-risk patients. <i>Translational Psychiatry</i> , 2020, 10, 300.	4.8	51
89	Insular volume abnormalities associated with different transition probabilities to psychosis. <i>Psychological Medicine</i> , 2012, 42, 1613-1625.	4.5	50
90	Inferior Frontal Cortex Modulation with an Acute Dose of Heroin During Cognitive Control. <i>Neuropsychopharmacology</i> , 2013, 38, 2231-2239.	5.4	50

#	ARTICLE	IF	CITATIONS
91	Prediction of conversion to psychosis in individuals with an at-risk mental state. <i>Current Opinion in Psychiatry</i> , 2017, 30, 209-219.	6.3	49
92	Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study. <i>Schizophrenia Research</i> , 2013, 147, 132-139.	2.0	48
93	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. <i>Biological Psychiatry</i> , 2020, 87, 243-252.	1.3	48
94	Radiological findings in individuals at high risk of psychosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 229-233.	1.9	47
95	Fine motor function and neuropsychological deficits in individuals at risk for schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006, 256, 201-206.	3.2	46
96	Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2019, 206, 67-74.	2.0	46
97	Modulation of motivational salience processing during the early stages of psychosis. <i>Schizophrenia Research</i> , 2015, 166, 17-23.	2.0	44
98	Reduced parahippocampal cortical thickness in subjects at ultra-high risk for psychosis. <i>Psychological Medicine</i> , 2014, 44, 489-498.	4.5	43
99	Sex Differences in Cognitive Functioning in At-Risk Mental State for Psychosis, First Episode Psychosis and Healthy Control Subjects. <i>European Psychiatry</i> , 2015, 30, 242-250.	0.2	43
100	Prediction of psychosis using neural oscillations and machine learning in neuroleptic-naïve at-risk patients. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 285-295.	2.6	43
101	EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis. <i>Schizophrenia Research</i> , 2010, 123, 208-216.	2.0	42
102	Alterations in the hippocampus and thalamus in individuals at high risk for psychosis. <i>NPJ Schizophrenia</i> , 2016, 2, 16033.	3.6	42
103	Estrogens and SERMS as adjunctive treatments for schizophrenia. <i>Frontiers in Neuroendocrinology</i> , 2019, 53, 100743.	5.2	42
104	Dysregulated Lipid Metabolism Precedes Onset of Psychosis. <i>Biological Psychiatry</i> , 2021, 89, 288-297.	1.3	42
105	Increased functional connectivity in the resting-state basal ganglia network after acute heroin substitution. <i>Translational Psychiatry</i> , 2015, 5, e533-e533.	4.8	41
106	NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders – medium-term follow-up and clinical course. <i>NPJ Schizophrenia</i> , 2018, 4, 11.	3.6	41
107	Abnormal effective connectivity and psychopathological symptoms in the psychosis high-risk state. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, 239-248.	2.4	39
108	Is age of onset in schizophrenia influenced by marital status?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 1992, 27, 122-128.	3.1	39

#	ARTICLE	IF	CITATIONS
109	Structural Network Disorganization in Subjects at Clinical High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw110.	4.3	38
110	Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 545-554.	2.6	37
111	Acute effects of heroin on emotions in heroin-dependent patients. <i>American Journal on Addictions</i> , 2013, 22, 598-604.	1.4	36
112	Impact of polygenic schizophrenia-related risk and hippocampal volumes on the onset of psychosis. <i>Translational Psychiatry</i> , 2016, 6, e868-e868.	4.8	36
113	Dysfunctional insular connectivity during reward prediction in patients with first-episode psychosis. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, 367-376.	2.4	36
114	Acute Effects of Intravenous Heroin on the Hypothalamic-Pituitary-Adrenal Axis Response. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 193-198.	1.4	35
115	Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in women. <i>Schizophrenia Research</i> , 2017, 189, 111-116.	2.0	35
116	Anterior cingulate pathology in the prodromal stage of schizophrenia. <i>NeuroImage</i> , 2008, 39, 553-554.	4.2	34
117	Orbitofrontal response to drug-related stimuli after heroin administration. <i>Addiction Biology</i> , 2015, 20, 570-579.	2.6	32
118	Does menopausal transition really influence mental health? Findings from the prospective long-term Zurich study. <i>World Psychiatry</i> , 2016, 15, 146-154.	10.4	32
119	Age-related brain structural alterations as an intermediate phenotype of psychosis. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, 307-319.	2.4	32
120	Schizophrenia – a disease of young single males?. <i>European Archives of Psychiatry and Neurological Sciences</i> , 1989, 239, 210-212.	0.9	31
121	Duration of untreated psychosis and cognitive functioning. <i>Schizophrenia Research</i> , 2013, 145, 43-49.	2.0	31
122	WFSBP and IAWMH Guidelines for the treatment of alcohol use disorders in pregnant women. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 17-50.	2.6	31
123	Gonadal function and its influence on psychopathology. <i>Archives of Women's Mental Health</i> , 1998, 1, 15-26.	2.6	30
124	The Self-screen-Prodrome as a short screening tool for pre-psychotic states. <i>Schizophrenia Research</i> , 2010, 123, 217-224.	2.0	30
125	Case management for schizophrenic patients at risk for rehospitalization: A case control study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1995, 246, 29-36.	3.2	29
126	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2019, 10, 345.	2.6	29



#	ARTICLE	IF	CITATIONS
127	Cost of attempted suicide: a retrospective study of extent and associated factors. <i>Swiss Medical Weekly</i> , 2012, 142, w13648.	1.6	29
128	Cannabis use and brain structural alterations of the cingulate cortex in early psychosis. <i>Psychiatry Research - Neuroimaging</i> , 2013, 214, 102-108.	1.8	28
129	The forthcoming role of treatment with oestrogens in mental health. <i>Swiss Medical Weekly</i> , 2007, 137, 565-72.	1.6	28
130	Late-onset Schizophrenia and Late Paraphrenia. <i>Schizophrenia Bulletin</i> , 1995, 21, 345-354.	4.3	27
131	Association of Frontal Gray Matter Volume and Cerebral Perfusion in Heroin Addiction: A Multimodal Neuroimaging Study. <i>Frontiers in Psychiatry</i> , 2013, 4, 135.	2.6	27
132	Reduction in Cerebral Perfusion after Heroin Administration: A Resting State Arterial Spin Labeling Study. <i>PLoS ONE</i> , 2013, 8, e71461.	2.5	27
133	Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people. <i>Schizophrenia Research</i> , 2020, 226, 44-51.	2.0	27
134	Oestrogens and schizophrenia. <i>Current Opinion in Psychiatry</i> , 2003, 16, 187-192.	6.3	26
135	EEG: a helpful tool in the prediction of psychosis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 257-262.	3.2	26
136	Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. <i>Psychological Medicine</i> , 2012, 42, 1461-1473.	4.5	26
137	Brain Diffusion Changes in Emerging Psychosis and the Impact of State-Dependent Psychopathology. <i>NeuroSignals</i> , 2015, 23, 71-83.	0.9	26
138	Duration of untreated psychosis/illness and brain volume changes in early psychosis. <i>Psychiatry Research</i> , 2017, 255, 332-337.	3.3	25
139	Individualized prediction of psychosis in subjects with an at-risk mental state. <i>Schizophrenia Research</i> , 2019, 214, 18-23.	2.0	25
140	Clinical and functional ultra-long-term outcome of patients with a clinical high risk (CHR) for psychosis. <i>European Psychiatry</i> , 2019, 62, 30-37.	0.2	24
141	Anatomical integrity within the inferior fronto-occipital fasciculus and semantic processing deficits in schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2020, 218, 267-275.	2.0	24
142	Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis. <i>JAMA Psychiatry</i> , 2020, 77, 190.	11.0	23
143	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. <i>Molecular Psychiatry</i> , 2021, 26, 4529-4543.	7.9	23
144	Negative symptoms in neuroleptic-naïve patients with first-episode psychosis correlate with QEEG parameters. <i>Schizophrenia Research</i> , 2009, 115, 231-236.	2.0	22

#	ARTICLE	IF	CITATIONS
145	Attempted Suicide in Immigrants from Turkey: A Comparison with Swiss Suicide Attempters. <i>Psychopathology</i> , 2012, 45, 366-373.	1.5	22
146	Cannabis use and cognitive functions in at-risk mental state and first episode psychosis. <i>Psychopharmacology</i> , 2013, 230, 299-308.	3.1	22
147	Abnormal functional integration of thalamic low frequency oscillation in the BOLD signal after acute heroin treatment. <i>Human Brain Mapping</i> , 2015, 36, 5287-5300.	3.6	22
148	Normalizing effect of heroin maintenance treatment on stress-induced brain connectivity. <i>Brain</i> , 2015, 138, 217-228.	7.6	22
149	Screening for Adult Attention-Deficit/Hyperactivity Disorder in a Psychiatric Outpatient Population with Specific Focus on Sex Differences. <i>Frontiers in Psychiatry</i> , 2017, 8, 115.	2.6	22
150	Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial. <i>Frontiers in Psychiatry</i> , 2019, 10, 393.	2.6	22
151	Gender differences in first self-perceived signs and symptoms in patients with an at-risk mental state and first episode psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 582-588.	1.7	22
152	Organic factors and the clinical features of late paranoid psychosis: a comparison with Alzheimer's disease and normal ageing. <i>Acta Psychiatrica Scandinavica</i> , 1994, 89, 335-340.	4.5	21
153	Estrogens and Schizophrenia. , 2005, , 31-52.		21
154	Classifying individuals at high-risk for psychosis based on functional brain activity during working memory processing. <i>NeuroImage: Clinical</i> , 2015, 9, 555-563.	2.7	21
155	The relationship between negative symptoms and cognitive functioning in patients at clinical high risk for psychosis. <i>Psychiatry Research</i> , 2018, 268, 21-27.	3.3	21
156	Cingulate Volume Abnormalities in Emerging Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 495-504.	1.9	21
157	Schizophrenic symptomatology varies with serum estradiol levels during menstrual cycle. <i>Schizophrenia Research</i> , 1992, 6, 114-115.	2.0	20
158	Evidence for an agitated-aggressive syndrome predating the onset of psychosis. <i>Schizophrenia Research</i> , 2014, 157, 26-32.	2.0	20
159	Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 292-299.	8.8	20
160	Higher morbidity risk for schizophrenia in males: Fact or fiction?. <i>Comprehensive Psychiatry</i> , 1994, 35, 39-49.	3.1	19
161	Early detection of psychosis: helpful or stigmatizing experience? A qualitative study. <i>Microbial Biotechnology</i> , 2018, 12, 66-73.	1.7	19
162	Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning – Results from the EU-GEI study. <i>European Psychiatry</i> , 2019, 59, 52-59.	0.2	19

#	ARTICLE	IF	CITATIONS
163	Suicide attempts in the county of Basel: results from the WHO/EURO Multicentre Study on Suicidal Behaviour. <i>Swiss Medical Weekly</i> , 2013, 143, w13759.	1.6	19
164	Dynamic prediction of transition to psychosis using joint modelling. <i>Schizophrenia Research</i> , 2018, 202, 333-340.	2.0	18
165	An overlapping pattern of cerebral cortical thinning is associated with both positive symptoms and aggression in schizophrenia via the ENIGMA consortium. <i>Psychological Medicine</i> , 2020, 50, 2034-2045.	4.5	18
166	The Impact of Diacetylmorphine on Hypothalamic-Pituitary-Adrenal Axis Activity and Heroin Craving in Heroin Dependence. <i>European Addiction Research</i> , 2012, 18, 116-123.	2.4	17
167	Are neurological soft signs pre-existing markers in individuals with an at-risk mental state for psychosis?. <i>Psychiatry Research</i> , 2013, 210, 427-431.	3.3	17
168	Relation between self-perceived stress, psychopathological symptoms and the stress hormone prolactin in emerging psychosis. <i>Journal of Psychiatric Research</i> , 2021, 136, 428-434.	3.1	17
169	Oestrogens and schizophrenia - Introduction. <i>Archives of Women's Mental Health</i> , 2002, 5, 91-92.	2.6	16
170	Can cognitive deficits facilitate differential diagnosis between at-risk mental state for psychosis and depressive disorders?. <i>Microbial Biotechnology</i> , 2013, 7, 381-390.	1.7	16
171	Altered prefrontal connectivity after acute heroin administration during cognitive control. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1375-1385.	2.1	16
172	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neupro trial. <i>Behaviour Research and Therapy</i> , 2020, 124, 103527.	3.1	16
173	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. <i>Molecular Psychiatry</i> , 2021, 26, 2590-2604.	7.9	16
174	The effects of antipsychotics on brain structure: what have we learnt from structural imaging of schizophrenia?. <i>Psychological Medicine</i> , 2009, 39, 1781-1782.	4.5	15
175	Increased superior frontal gyrus activation during working memory processing in psychosis: Significant relation to cumulative antipsychotic medication and to negative symptoms. <i>Schizophrenia Research</i> , 2016, 175, 20-26.	2.0	15
176	EEG Microstate Differences in Medicated vs. Medication-Naïve First-Episode Psychosis Patients. <i>Frontiers in Psychiatry</i> , 2020, 11, 600606.	2.6	15
177	Late-Onset Schizophrenia Versus Paranoid Psychoses: A Valid Diagnostic Distinction?. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 595-604.	1.2	15
178	Neurobiologically Based Stratification of Recent-Onset Depression and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes. <i>Biological Psychiatry</i> , 2022, 92, 552-562.	1.3	15
179	Superior temporal gray and white matter changes in schizophrenia or antipsychotic related effects?. <i>Schizophrenia Research</i> , 2009, 113, 109-110.	2.0	14
180	Insight and Hostility as Predictors and Correlates of Nonadherence in the European First Episode Schizophrenia Trial. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 258-261.	1.4	14

#	ARTICLE	IF	CITATIONS
181	Altered Insular Function during Aberrant Salience Processing in Relation to the Severity of Psychotic Symptoms. <i>Frontiers in Psychiatry</i> , 2016, 7, 189.	2.6	14
182	Sex differences in cognitive functioning of patients at-risk for psychosis and healthy controls: Results from the European Gene-Environment Interactions study. <i>European Psychiatry</i> , 2020, 63, e25.	0.2	14
183	Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis. <i>Schizophrenia Bulletin</i> , 2020, 46, 823-833.	4.3	14
184	Community care in child psychiatry. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 1991, 26, 28-33.	3.1	13
185	Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication. <i>NeuroImage: Clinical</i> , 2015, 8, 230-237.	2.7	13
186	Development and Validation of a Dynamic Risk Prediction Model to Forecast Psychosis Onset in Patients at Clinical High Risk. <i>Schizophrenia Bulletin</i> , 2019, 46, 252-260.	4.3	13
187	Effect of childhood physical abuse on social anxiety is mediated via reduced frontal lobe and amygdala-hippocampus complex volume in adult clinical high-risk subjects. <i>Schizophrenia Research</i> , 2021, 227, 101-109.	2.0	13
188	Orbitofrontal-Striatal Structural Alterations Linked to Negative Symptoms at Different Stages of the Schizophrenia Spectrum. <i>Schizophrenia Bulletin</i> , 2021, 47, 849-863.	4.3	13
189	Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?. <i>Current Pharmaceutical Design</i> , 2012, 18, 416-421.	1.9	12
190	Neural oscillations in antipsychotic-naïve patients with a first psychotic episode. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 296-307.	2.6	12
191	Sexually dimorphic subcortical brain volumes in emerging psychosis. <i>Schizophrenia Research</i> , 2018, 199, 257-265.	2.0	12
192	Neurocognition and Motor Functioning in the Prediction of Psychosis. <i>Key Issues in Mental Health</i> , 2016, , 116-132.	0.6	11
193	Correlations between self-rating and observer-rating of psychopathology in at-risk mental state and first-episode psychosis patients: influence of disease stage and gender. <i>Microbial Biotechnology</i> , 2017, 11, 461-470.	1.7	11
194	Survey of the European Psychiatric Association on the European status and perspectives in early detection and intervention in at-risk mental state and first-episode psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 853-858.	1.7	11
195	Relationship between jumping to conclusions and clinical outcomes in people at clinical high-risk for psychosis. <i>Psychological Medicine</i> , 2022, 52, 1569-1577.	4.5	11
196	Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population. <i>Microbial Biotechnology</i> , 2021, 15, 642-651.	1.7	11
197	Prediction of Caseness for Mental Pathology in Swiss Conscripts: The Self-Screen Prodrome. <i>Military Medicine</i> , 2009, 174, 1270-1275.	0.8	10
198	Violence against Women and Mental Health. <i>Key Issues in Mental Health</i> , 2013, , 167-174.	0.6	10

#	ARTICLE	IF	CITATIONS
199	Pituitary gland volume in at-risk mental state for psychosis: a longitudinal MRI analysis. <i>CNS Spectrums</i> , 2015, 20, 122-129.	1.2	10
200	Impact on the Onset of Psychosis of a Polygenic Schizophrenia-Related Risk Score and Changes in White Matter Volume. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 1201-1214.	1.6	10
201	Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach. <i>Scientific Reports</i> , 2019, 9, 8516.	3.3	10
202	Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis. <i>Microbial Biotechnology</i> , 2021, 15, 874-881.	1.7	10
203	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. <i>Schizophrenia Bulletin</i> , 2021, 47, 1018-1028.	4.3	10
204	Verbal memory performance predicts remission and functional outcome in people at clinical high-risk for psychosis. <i>Schizophrenia Research: Cognition</i> , 2022, 28, 100222.	1.3	10
205	Wilhelm Griesinger and the Concept of Community Care in 19th-Century Germany. <i>Psychiatric Services</i> , 1994, 45, 818-822.	2.0	9
206	Oestrogen-A Protective Factor in Schizophrenia?. <i>Current Psychiatry Reviews</i> , 2006, 2, 339-352.	0.9	9
207	Group Treatment for Depression in Mothers of Young Children Compared to Standard Individual Therapy. <i>Psychopathology</i> , 2013, 46, 94-101.	1.5	9
208	Can neuropsychological testing facilitate differential diagnosis between at-risk mental state (ARMS) for psychosis and adult attention-deficit/hyperactivity disorder (ADHD)?. <i>European Psychiatry</i> , 2018, 52, 38-44.	0.2	9
209	Predictors of study drop-out and service disengagement in patients at clinical high risk for psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2020, 55, 539-548.	3.1	9
210	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2022, 48, 100-110.	4.3	9
211	Changing patterns of mental health care in Germany. <i>International Journal of Law and Psychiatry</i> , 1996, 19, 391-411.	0.9	8
212	Cavum septum pellucidum in patients with first episode psychosis and individuals at high risk of psychosis. <i>European Psychiatry</i> , 2007, 22, 264-264.	0.2	8
213	Education and Reproductive Autonomy: The Case of Married Nigerian Women. <i>Narrative Inquiry in Bioethics</i> , 2017, 7, 231-244.	0.1	8
214	The neuropsychology of emerging psychosis and the role of working memory in episodic memory encoding. <i>Psychology Research and Behavior Management</i> , 2018, Volume 11, 157-168.	2.8	8
215	Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. <i>Schizophrenia Research</i> , 2020, 226, 52-60.	2.0	8
216	Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes. <i>Schizophrenia Research</i> , 2020, 216, 255-261.	2.0	8

#	ARTICLE	IF	CITATIONS
217	Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2020, 218, 48-54.	2.0	8
218	Cannabis and risk of psychosis. <i>Swiss Medical Weekly</i> , 2004, 134, 659-63.	1.6	8
219	Symptom Assessment in Casenotes and the Clinical Diagnosis of Schizophrenia. <i>Psychopathology</i> , 1995, 28, 131-139.	1.5	7
220	Longitudinal determinants of client treatment satisfaction in an intensive first-episode psychosis treatment programme. <i>Microbial Biotechnology</i> , 2017, 11, 354-362.	1.7	7
221	The Frankfurt Complaint Questionnaire for self-assessment of basic symptoms in the early detection of psychosis: Factor structure, reliability, and predictive validity. <i>International Journal of Methods in Psychiatric Research</i> , 2018, 27, e1600.	2.1	7
222	Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis. <i>Translational Psychiatry</i> , 2021, 11, 312.	4.8	7
223	Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processing. <i>ELife</i> , 2021, 10, .	6.0	7
224	High time for a paradigm shift in psychiatry. <i>World Psychiatry</i> , 2016, 15, 131-133.	10.4	6
225	Symptom Overlap and Screening for Symptoms of Attention-Deficit/Hyperactivity Disorder and Psychosis Risk in Help-Seeking Psychiatric Patients. <i>Frontiers in Psychiatry</i> , 2017, 8, 206.	2.6	6
226	Exploring the predictive power of the unspecific risk category of the Basel Screening Instrument for Psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 969-976.	1.7	6
227	Bride price payment and women's autonomy: Findings from qualitative interviews from Nigeria. <i>Women and Health</i> , 2019, 59, 775-788.	1.0	6
228	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. <i>Schizophrenia Research</i> , 2020, 230, 104-107.	2.0	6
229	Association between tobacco use and symptomatology in individuals at ultra-high risk to develop a psychosis: A longitudinal study. <i>Schizophrenia Research</i> , 2021, 236, 48-53.	2.0	6
230	Perinatal mental health service provision in Switzerland and in the UK. <i>Swiss Medical Weekly</i> , 2015, 145, w14011.	1.6	6
231	Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages. <i>JAMA Psychiatry</i> , 2022, 79, 677.	11.0	6
232	Late-Onset Schizophrenia Versus Paranoid Psychoses. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 595-604.	1.2	5
233	Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006, 10, 174-181.	2.4	5
234	The attenuated psychosis syndrome in DSM-5. <i>Schizophrenia Research</i> , 2013, 151, 295.	2.0	5

#	ARTICLE	IF	CITATIONS
235	Sex and gender differences in schizophrenic psychoses. <i>European Psychiatry</i> , 2016, 33, S46-S46.	0.2	5
236	T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION. <i>Schizophrenia Bulletin</i> , 2018, 44, S132-S133.	4.3	5
237	Implementation of early detection and intervention services for psychosis in Central and Eastern Europe: Current status. <i>Microbial Biotechnology</i> , 2019, 13, 1283-1288.	1.7	5
238	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. <i>Biological Psychiatry</i> , 2019, 85, e35-e39.	1.3	5
239	The association between migrant status and transition in an ultra-high risk for psychosis population. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 943-952.	3.1	5
240	Weibliche Rollen und psychische Gesundheit. , 2016, , 19-34.		5
241	Menopause and Mental Health. <i>Mental Health and Illness Worldwide</i> , 2020, , 147-173.	0.1	5
242	Patient-Identified Priorities Leading to Attempted Suicide. <i>Crisis</i> , 2018, 39, 37-46.	1.2	5
243	Basic Symptoms Are Associated With Age in Patients With a Clinical High-Risk State for Psychosis: Results From the PRONIA Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 552175.	2.6	5
244	Insular pathology in the at-risk mental state. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 254-255.	3.2	4
245	The role of vulnerability factors in individuals with an at-risk mental state of psychosis. <i>Neuropsychiatrie</i> , 2016, 30, 18-26.	2.5	4
246	Early Detection and Intervention in Psychosis. <i>Key Issues in Mental Health</i> , 2016, , 179-189.	0.6	4
247	Autonomy and Reproductive Rights of Married Ikwere Women in Rivers State, Nigeria. <i>Journal of Bioethical Inquiry</i> , 2017, 14, 205-215.	1.5	4
248	Machine Learning for Large-Scale Quality Control of 3D Shape Models in Neuroimaging. <i>Lecture Notes in Computer Science</i> , 2017, 10541, 371-378.	1.3	4
249	Therapist-client sex in psychotherapy: attitudes of professionals and students towards ethical arguments. <i>Swiss Medical Weekly</i> , 2015, 145, w14099.	1.6	4
250	Gender differences in the psychopathology of emerging psychosis. <i>Israel Journal of Psychiatry</i> , 2014, 51, 85-92.	0.2	4
251	Machine learning based prediction and the influence of complement " Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial. <i>Brain, Behavior, and Immunity</i> , 2022, 103, 50-60.	4.1	4
252	Central Institute of Mental Health, Mannheim, West Germany. <i>Psychological Medicine</i> , 1985, 15, 417-431.	4.5	3

#	ARTICLE	IF	CITATIONS
253	First self-perceived signs and symptoms in emerging psychosis compared with depression. <i>Microbial Biotechnology</i> , 2012, 6, 455-459.	1.7	3
254	Outcome of individuals "not at risk of psychosis" and prognostic accuracy of the Basel Screening Instrument for Psychosis (BSIP). <i>Microbial Biotechnology</i> , 2018, 12, 907-914.	1.7	3
255	Evaluating verbal learning and memory in patients with an at-risk mental state or first episode psychosis using structural equation modelling. <i>PLoS ONE</i> , 2018, 13, e0196936.	2.5	3
256	No associations between medial temporal lobe volumes and verbal learning/memory in emerging psychosis. <i>European Journal of Neuroscience</i> , 2019, 50, 3060-3071.	2.6	3
257	From Speech Illusions to Onset of Psychotic Disorder: Applying Network Analysis to an Experimental Measure of Aberrant Experiences. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	3
258	Do schizotypal or borderline personality disorders predict onset of psychotic disorder or persistent attenuated psychotic symptoms in patients at high clinical risk?. <i>Schizophrenia Research</i> , 2020, 220, 275-277.	2.0	3
259	Ä–strogene und Schizophrenie - Patientinnen an der Schnittstelle zwischen Psychiatrie und GynÄkologie. <i>Geburtshilfe Und Frauenheilkunde</i> , 2002, 62, 429-435.	1.8	2
260	Aneurysms of Pericallosal Cerebral Artery Haemorrhage with Consecutive Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 554-554.	2.3	2
261	Neural effects of heroin " Relation to anxiety stress. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 816-817.	4.8	2
262	Effects of an electronic reminder system on guideline-concordant treatment of psychotic disorders. <i>Neuropsychiatrie</i> , 2016, 30, 191-197.	2.5	2
263	Long-term rates of remission and late psychotic transition of individuals at risk for psychosis. <i>European Psychiatry</i> , 2017, 41, S186-S186.	0.2	2
264	Comorbidities in Patients with an At-risk Mental State and First Episode Psychosis. <i>European Psychiatry</i> , 2017, 41, S198-S198.	0.2	2
265	T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S116-S116.	4.3	2
266	Novel Gyrfication Networks Reveal Links with Psychiatric Risk Factors in Early Illness. <i>Cerebral Cortex</i> , 2021, , .	2.9	2
267	Psychotropic Drugs and the Perinatal Period. , 2016, , 79-92.		2
268	The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial. <i>Brain, Behavior, and Immunity</i> , 2022, 99, 147-156.	4.1	2
269	Hippocampal volume reduction specific for later transition to psychosis or substance-associated effects?. <i>Journal of Psychiatry and Neuroscience</i> , 2010, 35, 214-5; author reply 215.	2.4	2
270	Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	1.7	2



#	ARTICLE	IF	CITATIONS
271	Editorial: Sex and the Suffering Brain - A Call for Sex-Stratified Analyses in Psychiatric Research. <i>Frontiers in Psychiatry</i> , 2022, 13, 849009.	2.6	2
272	Latent state-trait structure of BPRS subscales in clinical high-risk state and first episode psychosis. <i>Scientific Reports</i> , 2022, 12, 6652.	3.3	2
273	STRATEGIES FOR IMPROVING THE PREDICTION OF PSYCHOSIS. <i>Schizophrenia Research</i> , 2008, 102, 155.	2.0	1
274	Poster #54 PITUITARY GLAND VOLUME IN INDIVIDUALS WITH AN AT-RISK MENTAL STATE: A LONGITUDINAL MRI ANALYSIS. <i>Schizophrenia Research</i> , 2012, 136, S300.	2.0	1
275	2710 " Gender differences in the psychopathology of emerging psychosis. <i>European Psychiatry</i> , 2013, 28, 1.	0.2	1
276	Alpha oscillations underlie working memory abnormalities in the psychosis high-risk state. <i>Biological Psychology</i> , 2017, 126, 12-18.	2.2	1
277	Estradiol Production Suppressed by Prolactin in at-risk Mental State and First Episode Psychosis Female Patients? Preliminary Results. <i>European Psychiatry</i> , 2017, 41, S267-S267.	0.2	1
278	Abnormal brain connectivity during error-monitoring in the psychosis high-risk state. <i>Schizophrenia Research</i> , 2018, 193, 261-262.	2.0	1
279	F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS. <i>Schizophrenia Bulletin</i> , 2018, 44, S228-S228.	4.3	1
280	S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING. <i>Schizophrenia Bulletin</i> , 2018, 44, S378-S379.	4.3	1
281	Voxel-Based Morphometry Correlates of an Agitated-Aggressive Syndrome in the At-Risk Mental State for Psychosis and First Episode Psychosis. <i>Scientific Reports</i> , 2018, 8, 16516.	3.3	1
282	O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL. <i>Schizophrenia Bulletin</i> , 2018, 44, S99-S99.	4.3	1
283	Vulnerability and Protective Factors for Mental Health: A Rereading in Gender Perspective. , 2019, , 25-36.		1
284	Increased Symptom Consolidation Preceding Transition to Psychosis: A Phenomenological Network Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
285	Controversial issues in climacteric medicine III: Hormone replacement therapy in climacteric and aging brain. <i>Gynecological Endocrinology</i> , 2003, 17, 363-378.	1.7	0
286	Group Psychotherapy for Depression in Early Stages of Motherhood. , 2005, 173, 167-181.		0
287	Indication and impact of mentoring models. <i>European Psychiatry</i> , 2007, 22, S24.	0.2	0
288	QEEG SPECTRAL POWER AND NEGATIVE SYMPTOMS IN THE DETECTION OF BEGINNING PSYCHOSIS. <i>Schizophrenia Research</i> , 2010, 117, 482-483.	2.0	0

#	ARTICLE	IF	CITATIONS
289	P.3.019 A meta-analysis of neuroimaging predictors of transition to psychosis. European Neuropsychopharmacology, 2010, 20, S78.	0.7	0
290	Poster #52 DURATION OF UNTREATED ILLNESS/PSYCHOSIS AND COGNITIVE FUNCTIONING. Schizophrenia Research, 2012, 136, S110.	2.0	0
291	Poster #56 INSULAR VOLUME ABNORMALITIES ASSOCIATED WITH DIFFERENT TRANSITION PROBABILITIES TO PSYCHOSIS – A VOXEL-BASED MORPHOMETRY STUDY. Schizophrenia Research, 2012, 136, S111.	2.0	0
292	S.10.03 Hyperprolactinemia in drug-naïve first-episode patients: data from EUFEST. European Neuropsychopharmacology, 2013, 23, S126.	0.7	0
293	P.6.d.001 Inhibition-specific prefrontal connectivity after an acute dose of heroin. European Neuropsychopharmacology, 2013, 23, S573-S574.	0.7	0
294	P.1.i.025 Abnormal brain functioning during salience processing in patients with schizophrenic psychosis. European Neuropsychopharmacology, 2013, 23, S277-S278.	0.7	0
295	THE PSYCHOSIS HIGH RISK STATE: IS IT VALID?. Schizophrenia Research, 2014, 153, S23-S24.	2.0	0
296	Early psychosis in young women. European Psychiatry, 2016, 33, S7-S7.	0.2	0
297	Early Detection of Psychosis - Helpful or Stigmatizing Experience for Those Concerned?. Key Issues in Mental Health, 0, , 69-82.	0.6	0
298	The Current European Status. European Psychiatry, 2017, 41, S27-S27.	0.2	0
299	The Relationship Between Negative Symptoms and Cognitive Functioning in Patients with an at Risk Mental State for Psychosis. European Psychiatry, 2017, 41, S270-S271.	0.2	0
300	Stigma in early detection of psychosis: Subjective experiences of those concerned. European Psychiatry, 2017, 41, S387-S387.	0.2	0
301	Letter from the Editor-in-Chief. Archives of Women's Mental Health, 2017, 20, 241-241.	2.6	0
302	Verbal Learning and Memory in At-risk Mental State and First Episode Psychosis Patients and Their Correlates to Brain Structural Alterations. European Psychiatry, 2017, 41, S103-S103.	0.2	0
303	Working Together for Early Detection of Psychosis. European Psychiatry, 2017, 41, S6-S6.	0.2	0
304	Letter from the Editor-in-Chief. Archives of Women's Mental Health, 2018, 21, 125-126.	2.6	0
305	T212. THE INTRINSIC ORGANIZATION OF SYMPTOMS MARKS TRANSITION FROM HIGH-RISK STATE TO EARLY PSYCHOSIS: A PHENOMENOLOGICAL CONNECTIVITY STUDY. Schizophrenia Bulletin, 2018, 44, S199-S199.	4.3	0
306	O6.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY. Schizophrenia Bulletin, 2019, 45, S177-S178.	4.3	0

#	ARTICLE	IF	CITATIONS
307	T21. DEVELOPMENT OF PROTEOMIC PREDICTION MODELS FOR OUTCOMES IN THE CLINICAL HIGH RISK STATE AND PSYCHOTIC EXPERIENCES IN ADOLESCENCE: MACHINE LEARNING ANALYSES IN TWO NESTED CASE-CONTROL STUDIES. Schizophrenia Bulletin, 2020, 46, S238-S239.	4.3	0
308	T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL. Schizophrenia Bulletin, 2020, 46, S244-S245.	4.3	0
309	Editorial. Archives of Women's Mental Health, 2020, 23, 739-740.	2.6	0
310	S175. CLINICAL OUTCOMES IN PEOPLE AT HIGH RISK FOR PSYCHOSIS RELATED TO INTERACTIONS BETWEEN POLYGENIC RISK SCORES AND CHILDHOOD ADVERSITY. Schizophrenia Bulletin, 2020, 46, S104-S104.	4.3	0
311	Title is missing!. Therapeutische Umschau Revue Therapeutique, 2010, 067, 0547-0547.	0.1	0
312	Traditional Methodology and Outcome Assessment in Studies on the Course of Schizophrenia. , 1999, , 249-258.		0
313	Appropriateness of Care and Joint Decision-Making Strategies. , 2016, , 207-209.		0
314	Menopause and Mental Health. Mental Health and Illness Worldwide, 2019, , 1-27.	0.1	0
315	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youth at Ultra-High Risk for Psychosis. SSRN Electronic Journal, 0, , .	0.4	0
316	Professional Conduct and Handling Misconduct in Psychotherapy: Ethical Practice between Boundaries, Relationships, and Reality. , 0, , 1001-1018.		0
317	Editorial: Women and the Pandemic. Archives of Women's Mental Health, 2022, 25, 255.	2.6	0
318	Gender and psychiatry. Israel Journal of Psychiatry, 2014, 51, 82-4.	0.2	0
319	The relationship between grey matter volume and clinical and functional outcomes in people at clinical high risk for psychosis. Schizophrenia Bulletin Open, 0, , .	1.7	0